NASDAQ:GLSI Greenwich LifeSciences (GLSI) Stock Price, News & Analysis → The Next Step of Their Control Is Here … (From Weiss Ratings) (Ad) Free GLSI Stock Alerts $13.12 +0.78 (+6.32%) (As of 04:27 PM ET) Add Compare Share Share Today's Range$12.30▼$13.2950-Day Range$11.24▼$20.3252-Week Range$7.58▼$21.44Volume26,292 shsAverage Volume45,295 shsMarket Capitalization$168.99 millionP/E RatioN/ADividend YieldN/APrice Target$36.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial Media Get Greenwich LifeSciences alerts: Email Address Greenwich LifeSciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside176.9% Upside$36.00 Price TargetShort InterestHealthy3.17% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.03Based on 2 Articles This WeekInsider TradingAcquiring Shares$327,722 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.30 out of 5 starsMedical Sector419th out of 908 stocksPharmaceutical Preparations Industry187th out of 424 stocks 3.5 Analyst's Opinion Consensus RatingGreenwich LifeSciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageGreenwich LifeSciences has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.17% of the float of Greenwich LifeSciences has been sold short.Short Interest Ratio / Days to CoverGreenwich LifeSciences has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Greenwich LifeSciences has recently increased by 31.74%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldGreenwich LifeSciences does not currently pay a dividend.Dividend GrowthGreenwich LifeSciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GLSI. Previous Next 1.7 News and Social Media Coverage News SentimentGreenwich LifeSciences has a news sentiment score of 0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.33 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Greenwich LifeSciences this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for GLSI on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Greenwich LifeSciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $327,722.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders52.86% of the stock of Greenwich LifeSciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 4.16% of the stock of Greenwich LifeSciences is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Greenwich LifeSciences is -18.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Greenwich LifeSciences is -18.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGreenwich LifeSciences has a P/B Ratio of 25.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About Greenwich LifeSciences Stock (NASDAQ:GLSI)Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.Read More GLSI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GLSI Stock News HeadlinesApril 4, 2024 | insidertrades.comSnehal Patel Buys 3,000 Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) StockMarch 27, 2024 | insidertrades.comGreenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel Acquires 2,500 SharesApril 26, 2024 | Weiss Ratings (Ad)The Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.April 25, 2024 | americanbankingnews.comGreenwich LifeSciences (NASDAQ:GLSI) Shares Down 4% April 17, 2024 | americanbankingnews.comGreenwich LifeSciences (NASDAQ:GLSI) versus Zai Lab (NASDAQ:ZLAB) Head-To-Head AnalysisApril 15, 2024 | markets.businessinsider.comGLSI Stock Earnings: Greenwich LifeSciences Misses EPS for Q4 2023March 13, 2024 | globenewswire.comGreenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025March 12, 2024 | globenewswire.comGreenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in EuropeApril 26, 2024 | Weiss Ratings (Ad)The Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.March 7, 2024 | finance.yahoo.comGreenwich LifeSciences Inc (GLSI) CEO and CFO, 10% Owner Snehal Patel Acquires Additional SharesFebruary 28, 2024 | markets.businessinsider.comExpanding Horizons: Bullish Buy Rating as Greenwich LifeSciences’s Breast Cancer Trial Goes Pan-EuropeanFebruary 27, 2024 | msn.comGreenwich LifeSciences stock jumps 8% on Phase 3 study expansionFebruary 27, 2024 | finanznachrichten.deGreenwich LifeSciences, Inc.: Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European CountriesFebruary 27, 2024 | globenewswire.comGreenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European CountriesFebruary 23, 2024 | benzinga.comGreenwich LifeSciences Stock (NASDAQ:GLSI) Dividends: History, Yield and DatesFebruary 22, 2024 | finanznachrichten.deGreenwich LifeSciences, Inc.: Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European RegulatorsFebruary 22, 2024 | msn.comGreenwich Lifesciences announces acceptance for Flamingo-01 trial by EMAFebruary 22, 2024 | finance.yahoo.comGreenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European RegulatorsFebruary 22, 2024 | globenewswire.comGreenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European RegulatorsFebruary 21, 2024 | realmoney.thestreet.com2 Rare Insider Buys in a Frothy MarketFebruary 20, 2024 | markets.businessinsider.comHC Wainwright & Co. Maintains Buy Rating for Greenwich LifeSciences: Here's What You Need To KnowFebruary 14, 2024 | msn.comWhy Greenwich Lifesciences (GLSI) Stock Is SkyrocketingFebruary 14, 2024 | morningstar.comGreenwich LifeSciences Shares Rise as Company Prepares FDA Filing for Breast Cancer ImmunotherapyFebruary 14, 2024 | globenewswire.comGreenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01December 21, 2023 | bbc.co.ukGreenwich: Closed pub reopens as community hubDecember 11, 2023 | finance.yahoo.comInsiders hold 54% of Greenwich LifeSciences, Inc. (NASDAQ:GLSI), and they've been buying recentlyDecember 2, 2023 | yahoo.comGreenwich, United States - Weather Forecasts | Maps | News - Yahoo WeatherSee More Headlines Receive GLSI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Greenwich LifeSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/15/2024Today4/26/2024Next Earnings (Estimated)5/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GLSI CUSIPN/A CIK1799788 Webwww.greenwichlifesciences.com Phone832-819-3232FaxN/AEmployees3Year FoundedN/APrice Target and Rating Average Stock Price Target$36.00 High Stock Price Target$36.00 Low Stock Price Target$36.00 Potential Upside/Downside+191.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,890,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-93.88% Return on Assets-91.17% Debt Debt-to-Equity RatioN/A Current Ratio23.77 Quick Ratio23.77 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.52 per share Price / Book23.73Miscellaneous Outstanding Shares12,880,000Free Float6,071,000Market Cap$158.94 million OptionableNot Optionable Beta1.38 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Snehal S. Patel (Age 61)CEO, CFO & Director Comp: $1.01MMr. Eric Rothe (Age 49)Founder & Independent Director Dr. Frank Joseph Daugherty M.D. (Age 74)Chief Medical Officer & Director Dr. Jaye L. Thompson Ph.D. (Age 58)Vice President Clinical & Regulatory Affairs Dr. Christine T. Fischette Ph.D. (Age 73)VP of Business Development Key CompetitorsGossamer BioNASDAQ:GOSSscPharmaceuticalsNASDAQ:SCPHTelomir PharmaceuticalsNASDAQ:TELOAdicet BioNASDAQ:ACETInventivaNASDAQ:IVAView All CompetitorsInsidersSnehal PatelBought 3,000 shares on 4/1/2024Total: $57,240.00 ($19.08/share)Snehal PatelBought 2,500 shares on 3/22/2024Total: $49,950.00 ($19.98/share)Snehal PatelBought 1,500 shares on 3/20/2024Total: $26,520.00 ($17.68/share)Snehal PatelBought 4,100 shares on 3/4/2024Total: $53,423.00 ($13.03/share)Snehal PatelBought 12,700 shares on 2/15/2024Total: $140,589.00 ($11.07/share)View All Insider Transactions GLSI Stock Analysis - Frequently Asked Questions Should I buy or sell Greenwich LifeSciences stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Greenwich LifeSciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" GLSI shares. View GLSI analyst ratings or view top-rated stocks. What is Greenwich LifeSciences' stock price target for 2024? 1 equities research analysts have issued 1 year price objectives for Greenwich LifeSciences' shares. Their GLSI share price targets range from $36.00 to $36.00. On average, they anticipate the company's stock price to reach $36.00 in the next twelve months. This suggests a possible upside of 176.9% from the stock's current price. View analysts price targets for GLSI or view top-rated stocks among Wall Street analysts. How have GLSI shares performed in 2024? Greenwich LifeSciences' stock was trading at $10.52 on January 1st, 2024. Since then, GLSI shares have increased by 23.6% and is now trading at $13.00. View the best growth stocks for 2024 here. Are investors shorting Greenwich LifeSciences? Greenwich LifeSciences saw a increase in short interest in April. As of April 15th, there was short interest totaling 185,100 shares, an increase of 31.7% from the March 31st total of 140,500 shares. Based on an average trading volume of 51,000 shares, the days-to-cover ratio is currently 3.6 days. Currently, 3.2% of the shares of the stock are short sold. View Greenwich LifeSciences' Short Interest. When is Greenwich LifeSciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 27th 2024. View our GLSI earnings forecast. How were Greenwich LifeSciences' earnings last quarter? Greenwich LifeSciences, Inc. (NASDAQ:GLSI) released its quarterly earnings results on Monday, April, 15th. The company reported ($0.21) earnings per share (EPS) for the quarter. When did Greenwich LifeSciences IPO? Greenwich LifeSciences (GLSI) raised $7 million in an IPO on Friday, September 25th 2020. The company issued 1,300,000 shares at a price of $5.75 per share. Aegis Capital served as the underwriter for the IPO. How do I buy shares of Greenwich LifeSciences? Shares of GLSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GLSI) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithMan Who Predicted 2008: “This Will be Worse.”AltimetryFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Greenwich LifeSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
